Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Revenue (2016 - 2024)

Kiora Pharmaceuticals' Revenue history spans 9 years, with the latest figure at $16.0 million for Q1 2024.

  • For Q1 2024, Revenue changed N/A year-over-year to $16.0 million; the TTM value through Dec 2024 reached $16.0 million, changed N/A, while the annual FY2024 figure was $16.0 million, N/A changed from the prior year.
  • Revenue reached $16.0 million in Q1 2024 per KPRX's latest filing, up from -$937.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $16.0 million in Q1 2024 to a low of -$4132.0 in Q4 2021.
  • Average Revenue over 4 years is $2.7 million, with a median of -$811.5 recorded in 2021.
  • The largest YoY upside for Revenue was 134.26% in 2021 against a maximum downside of 134.26% in 2021.
  • A 4-year view of Revenue shows it stood at $12059.0 in 2020, then crashed by 134.26% to -$4132.0 in 2021, then soared by 77.32% to -$937.0 in 2022, then skyrocketed by 1707677.37% to $16.0 million in 2024.
  • Per Business Quant, the three most recent readings for KPRX's Revenue are $16.0 million (Q1 2024), -$937.0 (Q3 2022), and -$4132.0 (Q4 2021).